Free Trial
NASDAQ:ETON

Eton Pharmaceuticals Q4 2024 Earnings Report

Eton Pharmaceuticals logo
$17.30 +0.21 (+1.23%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$17.26 -0.05 (-0.26%)
As of 08/22/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eton Pharmaceuticals EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.02
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Eton Pharmaceuticals Revenue Results

Actual Revenue
$11.65 million
Expected Revenue
$10.53 million
Beat/Miss
Beat by +$1.12 million
YoY Revenue Growth
N/A

Eton Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 18, 2025
Conference Call Time
10:00AM ET

Upcoming Earnings

Eton Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Eton Pharmaceuticals Earnings Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.tc pixel
See More Eton Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eton Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eton Pharmaceuticals and other key companies, straight to your email.

About Eton Pharmaceuticals

Eton Pharmaceuticals (NASDAQ:ETON), a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

View Eton Pharmaceuticals Profile

More Earnings Resources from MarketBeat